OCUL

Ocular Therapeutix Inc

Feb 05 • 04:00PM ET

8.91

+0.36 4.21 %

Healthcare • Biotechnology • USA • NASD

Peers: LLY GILD JNJ AMGN BIIB BMRN ALKS INCY AGIO ELAN

| Held by: VTI IWM VXF IWO VTWO PJP SCHA VHT IHE XPH

Index	RUT	P/E	-	EPS (ttm)	-1.44	Insider Own	12.61%	Shs Outstand	215.93M	Perf Week	-10.45%
Market Cap	1.90B	Forward P/E	-	EPS next Y	-1.23	Insider Trans	-0.47%	Shs Float	186.18M	Perf Month	-20.80%
Enterprise Value	1.24B	PEG	-	EPS next Q	-0.32	Inst Own	80.44%	Short Float	6.87%	Perf Quarter	-18.26%
Income	-265.94M	P/S	36.54	EPS this Y	5.36%	Inst Trans	19.50%	Short Ratio	3.11	Perf Half Y	-28.72%
Sales	51.95M	P/B	2.94	EPS next Y	8.60%	ROA	-42.01%	Short Interest	12.79M	Perf YTD	-26.61%
Book/sh	3.03	P/C	2.57	EPS next 5Y	12.01%	ROE	-54.85%	52W High	16.44 -45.80%	Perf Year	13.94%
Cash/sh	3.47	P/FCF	-	EPS past 3/5Y	-15.40% 11.13%	ROIC	-36.51%	52W Low	5.78 54.02%	Perf 3Y	127.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.29% 24.45%	Gross Margin	84.95%	Volatility	8.68% 8.02%	Perf 5Y	-50.91%
Dividend TTM	-	EV/Sales	23.80	EPS Y/Y TTM	-14.01%	Oper. Margin	-519.75%	ATR (14)	0.78	Perf 10Y	51.53%
Dividend Ex-Date	-	Quick Ratio	15.32	Sales Y/Y TTM	-18.47%	Profit Margin	-511.90%	RSI (14)	31.42	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	15.39	EPS Q/Q	-0.69%	SMA20	-14.27%	Beta	0.90	Target Price	25.23
Payout	-	Debt/Eq	0.12	Sales Q/Q	-22.43%	SMA50	-25.01%	Rel Volume	2.24	Prev Close	8.55
Employees	325	LT Debt/Eq	0.11	Earnings	Feb 05 BMO	SMA200	-18.44%	Avg Volume	4.11M	Price	8.91
IPO	Jul 25, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.63% -17.85%	Trades		Volume	8,948,515	Change	4.21%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-25	Initiated	Chardan Capital Markets	Buy	$21
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$17
Mar-11-25	Initiated	Needham	Buy	$15
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy	$7 → $11
May-31-24	Resumed	Piper Sandler	Overweight	$15
Feb-09-24	Initiated	BofA Securities	Buy	$15
Apr-21-23	Initiated	Robert W. Baird	Outperform	$18
Aug-10-22	Resumed	Berenberg	Buy	$15
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy	$17
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy	$27
Nov-13-20	Reiterated	Raymond James	Strong Buy	$15 → $25
Aug-10-20	Reiterated	H.C. Wainwright	Buy	$10 → $13
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Reiterated	H.C. Wainwright	Buy	$12 → $9
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform	$11 → $5
May-21-19	Downgrade	Cowen	Outperform → Market Perform	$13 → $3
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight	$22 → $24

Show Previous Ratings

Feb-05-26 04:06PM	Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates (StockStory)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Jan-26-26 10:34PM	A Look Back at Pharmaceuticals Stocks' Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack (StockStory) +6.04%
04:01PM	Loading…
Jan-23-26 04:01PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.64%
Jan-21-26 07:00AM	Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer (GlobeNewswire)
Jan-15-26 04:25PM	Stocks to Watch Thursday: Penumbra, BlackRock, Goldman Sachs (The Wall Street Journal)
04:20PM	Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid (Investor's Business Daily)
01:03PM	Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory (Insider Monkey)
10:30AM	Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid (Benzinga)
09:47AM	Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid (Investor's Business Daily)
09:37AM	Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock (The Wall Street Journal)
09:26AM	Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength? (Zacks)
Jan-13-26 11:04PM	3 Reasons OCUL is Risky and 1 Stock to Buy Instead (StockStory) +6.14%
06:07PM	Loading…
Jan-02-26 06:07PM	Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales (StockStory)
Dec-31-25 11:25AM	BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD (Insider Monkey)
Dec-11-25 07:44AM	H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission (Insider Monkey)
Dec-09-25 02:23PM	Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application (Insider Monkey)
Dec-08-25 07:00AM	Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD (GlobeNewswire) +28.06%
Dec-05-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 07:00AM	Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI in NPDR (GlobeNewswire)
Nov-20-25 09:55AM	Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet (Zacks)
Nov-18-25 12:44AM	Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences (Insider Monkey)
Nov-12-25 01:37PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
07:00AM	Ocular Therapeutix to Participate in November and December Investor Conferences (GlobeNewswire)
Nov-10-25 08:16PM	RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory (Insider Monkey)
Nov-07-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:02PM	Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
08:45AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:43AM	Loading…
07:43AM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
07:00AM	Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R (GlobeNewswire)
Nov-03-25 07:33AM	Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 09:55AM	Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade (Zacks)
Oct-28-25 07:00AM	Ocular Therapeutix to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-24-25 09:55AM	Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-17-25 09:54PM	H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating (Insider Monkey)
Oct-08-25 12:57AM	Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 (Insider Monkey)
Oct-07-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Scientific Conferences (GlobeNewswire) +5.01%
Oct-02-25 12:46AM	Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale (Insider Monkey)
Sep-30-25 07:08AM	Ocular Therapeutix Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -6.70%
06:21AM	Ocular Therapeutix Investor Day to Highlight Exceptional AXPAXLI Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint (GlobeNewswire)
Sep-24-25 04:06AM	Chardan Capital Initiates Ocular Therapeutix (OCUL) With a Buy Rating (Insider Monkey)
Sep-08-25 07:00AM	Ocular Therapeutix to Host Investor Day on September 30, 2025 (GlobeNewswire) -6.54%
Aug-27-25 07:00AM	Ocular Therapeutix to Participate in September Investor and Scientific Conferences (GlobeNewswire)
Aug-12-25 07:00AM	Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI in NPDR (GlobeNewswire)
Aug-05-25 08:25AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:25AM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Aug-04-25 09:37AM	Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-29-25 07:00AM	Ocular Therapeutix to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-22-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Scientific Conferences (GlobeNewswire)
Jun-26-25 01:54PM	Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company (GlobeNewswire)
Jun-25-25 11:13AM	Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? (Zacks)
Jun-16-25 07:00AM	Ocular Therapeutix to Participate in Clinical Trials at the Summit (CTS) 2025 (GlobeNewswire)
May-28-25 07:00AM	Ocular Therapeutix To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI in Wet Age-Related Macular Degeneration (GlobeNewswire) +13.69%
May-14-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-05-25 08:15AM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -12.16%
07:11AM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights (GlobeNewswire)
May-02-25 09:25AM	Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:00AM	Ocular Therapeutix to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Apr-28-25 07:00AM	Ocular Therapeutix to Report First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +5.45%
Apr-11-25 04:30PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.01% +6.47%
Mar-31-25 07:00AM	Ocular Therapeutix to Participate in Two Investor Conferences in April (GlobeNewswire)
Mar-14-25 08:36AM	Why Ocular Therapeutix Was Bumping Higher This Week (Motley Fool)
Mar-11-25 02:49PM	Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside (Benzinga) +11.24%
Mar-07-25 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 02:00AM	Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com) +9.70%
Mar-03-25 11:41PM	Q4 2024 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) -17.02%
08:15AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:19AM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-28-25 07:10AM	Ocular Therapeutix Inc (OCUL) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-25 07:00AM	Ocular Therapeutix to Present at Two Investor Conferences in March (GlobeNewswire)
Feb-24-25 07:00AM	Ocular Therapeutix to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025 (GlobeNewswire)
Feb-03-25 07:00AM	Ocular Therapeutix Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting (GlobeNewswire)
Jan-17-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-25 07:00AM	Ocular Therapeutix Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI in NPDR (GlobeNewswire)
Jan-08-25 07:00AM	Ocular Therapeutix to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation (GlobeNewswire)
Dec-13-24 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-24 07:30AM	Ocular Therapeutix to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-03-24 07:47AM	Ocular Therapeutix announces over 300 subjects randomized in SOL-1 (TipRanks)
Dec-02-24 07:30AM	Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1 (GlobeNewswire)
Nov-26-24 07:30AM	Ocular Therapeutix to Participate in December Investor and Scientific Conferences (GlobeNewswire) +7.26%
Nov-15-24 02:06AM	Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com) -7.66%
Nov-14-24 08:40AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.42%
07:37AM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Third Quarter 2024 Results and Business Highlights (GlobeNewswire)
Nov-13-24 07:30AM	Ocular Therapeutix to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV (GlobeNewswire)
07:17AM	What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings (GuruFocus.com)
Nov-12-24 07:30AM	Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business Officer (GlobeNewswire)
Nov-06-24 07:30AM	Ocular Therapeutix to Report Third Quarter 2024 Results on November 14, 2024 (GlobeNewswire)
Oct-15-24 07:30AM	Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Oct-14-24 09:59AM	Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? (Zacks) +6.95%
Oct-09-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Ocular Therapeutix to Present at October Ophthalmology Meetings (GlobeNewswire)
Oct-08-24 08:50AM	Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength (Zacks)

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Notman Donald	Chief Operating Officer	Feb 04 '26	Sale	8.54	6,035	51,539	377,802	Feb 04 08:23 PM
Notman Donald	Chief Operating Officer	Feb 02 '26	Sale	9.14	5,455	49,859	383,837	Feb 04 08:23 PM
STEVE MEYERS	Officer	Feb 04 '26	Proposed Sale	8.54	4,408	37,636		Feb 04 04:10 PM
DONALD D NOTMAN JR.	Officer	Feb 04 '26	Proposed Sale	8.54	6,035	51,541		Feb 04 04:09 PM
DONALD D NOTMAN JR.	Officer	Feb 02 '26	Proposed Sale	9.14	5,455	49,873		Feb 02 04:29 PM
STEVE MEYERS	Officer	Feb 02 '26	Proposed Sale	9.14	3,052	27,904		Feb 02 04:28 PM
Nayak Sanjay	Chief Strategy Officer	Nov 24 '25	Sale	12.04	1,878	22,611	277,860	Nov 26 04:02 PM
Dugel Pravin	See Remarks	Nov 24 '25	Sale	12.04	19,530	235,141	3,157,960	Nov 26 04:02 PM
Kaiser Peter	Chief Development Officer	Nov 24 '25	Sale	12.02	3,007	36,144	191,433	Nov 26 04:01 PM
Heier Jeffrey S.	Chief Scientific Officer	Nov 24 '25	Sale	12.04	3,469	41,767	245,940	Nov 26 04:01 PM
PRAVIN DUGEL	Officer	Nov 24 '25	Proposed Sale	12.04	19,530	235,083		Nov 24 04:33 PM
SANJAY NAYAK	Officer	Nov 24 '25	Proposed Sale	12.04	1,878	22,616		Nov 24 04:31 PM
PETER KAZUO KAISER	Officer	Nov 24 '25	Proposed Sale	12.02	3,007	36,150		Nov 24 04:30 PM
JEFFREY S. HEIER	Officer	Nov 24 '25	Proposed Sale	12.04	3,469	41,772		Nov 24 04:28 PM
Saroj Namrata	Chief Business Officer	Nov 05 '25	Sale	10.74	25,865	277,790	174,135	Nov 07 04:01 PM
NAMRATA SAROJ	Officer	Nov 05 '25	Proposed Sale	10.74	25,865	277,909		Nov 05 04:20 PM
Anderman Todd	Chief Legal Officer	Oct 08 '25	Sale	12.34	11,132	137,369	87,568	Oct 10 04:01 PM
TODD ANDERMAN	Officer	Oct 08 '25	Proposed Sale	12.34	11,132	137,400		Oct 08 04:03 PM
Kaiser Peter	Chief Development Officer	Oct 02 '25	Sale	11.03	9,653	106,473	194,440	Oct 06 05:13 PM
Heier Jeffrey S.	Chief Scientific Officer	Oct 02 '25	Sale	11.04	10,502	115,942	249,409	Oct 06 05:10 PM
JEFFREY S. HEIER	Officer	Oct 02 '25	Proposed Sale	11.04	10,502	115,890		Oct 02 04:11 PM
PETER KAZUO KAISER	Officer	Oct 02 '25	Proposed Sale	11.03	9,653	106,516		Oct 02 04:08 PM
Notman Donald	See Remarks	Sep 02 '25	Sale	12.43	1,066	13,250	308,807	Sep 04 04:50 PM
DONALD D NOTMAN JR.	Officer	Sep 02 '25	Proposed Sale	12.43	1,066	13,245		Sep 02 04:10 PM
Kaiser Peter	Chief Development Officer	Aug 25 '25	Sale	12.04	3,011	36,252	204,093	Aug 27 06:44 PM
Nayak Sanjay	Chief Strategy Officer	Aug 25 '25	Sale	12.04	1,885	22,695	279,738	Aug 27 06:43 PM
Heier Jeffrey S.	Chief Scientific Officer	Aug 25 '25	Sale	12.04	3,063	36,879	259,911	Aug 27 06:42 PM
Dugel Pravin	See Remarks	Aug 25 '25	Sale	12.04	21,494	258,788	3,227,244	Aug 27 06:41 PM
PRAVIN DUGEL	Officer	Aug 25 '25	Proposed Sale	12.04	21,494	258,758		Aug 25 04:19 PM
SANJAY NAYAK	Officer	Aug 25 '25	Proposed Sale	12.04	1,885	22,702		Aug 25 04:18 PM
JEFFREY S. HEIER	Officer	Aug 25 '25	Proposed Sale	12.04	3,063	36,883		Aug 25 04:17 PM
PETER KAZUO KAISER	Officer	Aug 25 '25	Proposed Sale	12.04	3,011	36,253		Aug 25 04:16 PM
Waheed Nadia	Chief Medical Officer	Jun 02 '25	Sale	8.05	13,861	111,581	206,805	Jun 03 04:20 PM
NADIA K. WAHEED	Officer	Jun 02 '25	Proposed Sale	8.05	13,861	111,524		Jun 02 04:40 PM
Nayak Sanjay	Chief Strategy Officer	May 23 '25	Sale	7.17	1,862	13,351	281,623	May 27 05:42 PM
Kaiser Peter	Chief Development Officer	May 23 '25	Sale	7.17	2,974	21,324	207,104	May 27 05:40 PM
Heier Jeffrey S.	Chief Scientific Officer	May 23 '25	Sale	7.18	3,024	21,712	262,974	May 27 05:39 PM
Dugel Pravin	See Remarks	May 23 '25	Sale	7.18	21,219	152,352	3,499,099	May 27 05:37 PM
PETER KAZUO KAISER	Officer	May 23 '25	Proposed Sale	7.17	2,974	21,323		May 23 04:14 PM
JEFFREY S. HEIER	Officer	May 23 '25	Proposed Sale	7.18	3,024	21,707		May 23 04:11 PM
PRAVIN DUGEL	Officer	May 23 '25	Proposed Sale	7.18	21,219	152,289		May 23 04:08 PM
SANJAY NAYAK	Officer	May 23 '25	Proposed Sale	7.17	1,862	13,347		May 23 04:07 PM
LINDSTROM RICHARD L MD	Director	May 08 '25	Buy	6.96	10,000	69,600	172,704	May 12 08:50 PM
Dugel Pravin	See Remarks	Feb 24 '25	Sale	6.87	21,475	147,533	3,520,318	Feb 26 06:27 PM
Heier Jeffrey S.	Chief Scientific Officer	Feb 24 '25	Sale	6.87	3,061	21,029	265,998	Feb 26 06:25 PM
Kaiser Peter	Chief Development Officer	Feb 24 '25	Sale	6.87	3,009	20,672	210,078	Feb 26 06:24 PM
Nayak Sanjay	Chief Strategy Officer	Feb 24 '25	Sale	6.84	1,895	12,962	283,485	Feb 26 06:22 PM
PETER KAZUO KAISER	Officer	Feb 24 '25	Proposed Sale	6.87	3,009	20,684		Feb 24 04:54 PM
JEFFREY S. HEIER	Officer	Feb 24 '25	Proposed Sale	6.87	3,061	21,043		Feb 24 04:33 PM
PRAVIN DUGEL	Officer	Feb 24 '25	Proposed Sale	6.87	21,475	147,617		Feb 24 04:32 PM
SANJAY NAYAK	Officer	Feb 24 '25	Proposed Sale	6.84	1,895	12,957		Feb 24 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCUL

Ocular Therapeutix Inc

Upgrade your FINVIZ experience